Among many of the insights provided in the IQVIA Institute for Human Data Science report “Global Medicine Spending and Usage Trends: Outlook to 2024,” global medicine spending is projected to increase from 2 percent to 5 percent annually through 2024 on a net basis, compared to 4.2 percent in the past five years.
A cheaper HIV prevention pill is going on sale in the United States, but experts say the price drop will not help as many people if doctors instead prescribe a newer, more expensive brand-name drug.
The U.S. Food and Drug Administration granted Breakthrough Therapy designation to Genentech’s Esbriet as a potential treatment for adults with unclassifiable interstitial lung disease (uILD) as the Roche subsidiary looks to expand the drug’s indications.
One of the arguments biopharma companies make for the high cost of new drugs is the expense of drug development. A new study published in JAMA Network, “Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the U.S., 2007-2018,” provides some concrete data to the argument.
Neurelis Inc. announced the commercial availability of Valtoco (diazepam nasal spray) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in adult and pediatric patients 6 years of age and older.
More than 17.6 million American adults (about 7.5 percent) experience allergic rhinitis (also called hay fever or seasonal allergies). Many different substances (called allergens) can trigger allergic rhinitis, such as tree or grass pollen, and each person has their own set of problematic allergens.
With impeachment behind us and the elections looming, both parties are focused on healthcare, the policy topic of greatest concern to voters. More specifically, they are focused on lowering the cost of prescription drugs.
As the 2020 presidential election looms, debate about the price of prescription drugs and healthcare will intensify; healthcare communication leaders share their thoughts on how their pharma clients can be a constructive part of the conversations.
On Valentine’s Day, BioSpace would be remiss not to mention, er, matters of the heart. There are reportedly 59 life sciences companies or organizations worldwide that focus on the cardiovascular system, ranging from the Aab Cardiovascular Research Institute based in West Henrietta, New York to XyloCor Therapeutics, with headquarters in Philadelphia. That number is probably low.
Treatment with Stelara is resulting in positive outcomes for patients with Crohn’s disease, as Janssen Pharmaceutical said 79% of patients in a late-stage trial showed a clinical response to the medication and 67% were in clinical remission.